Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on October 11, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print October 11, 2007, doi: 10.1161/ATVBAHA.107.153221
A more recent version of this article appeared on December 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/12/2783    most recent
ATVBAHA.107.153221v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carter, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, A. M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Metabolic Syndrome

Submitted on June 6, 2007
Accepted on September 28, 2007

Heritability of Clot Formation, Morphology, and Lysis. The EuroCLOT Study

Angela M. Carter ; Charlotte M. Cymbalista ; Tim D. Spector ; Peter J. Grant *; on behalf of the EuroCLOT Investigators

From the Academic Unit of Molecular Vascular Medicine (A.M.C., C.M.C., P.J.G.), The LIGHT Laboratories, University of Leeds, UK; and Twin Research & Genetic Epidemiology Unit (T.D.S.), King’s College London, London, UK.

* To whom correspondence should be addressed. E-mail: P.J.Grant{at}leeds.ac.uk.

Objective—The relative balance between clot formation and fibrinolysis is considered to reflect thrombotic potential following vascular injury (1) to determine the contribution of genetic and environmental factors to variance in measures of clot structure/function in the Leeds Family Study, and (2) to determine the relationship between measures of clot structure/function and cardiovascular risk.

Methods and Results—Using high throughput turbidimetric assays, heritabilities of measures of clot formation, clot structure, and clot lysis were {approx}0.30. Fibrinogen contributed to variance in all measures and plasminogen activator inhibitor-1 to variance in lysis variables. Subjects at increased cardiovascular risk attributable to the presence of the metabolic syndrome (MetS) had increased clot density (MaxAbsC: 0.358 [0.340, 0.375]au) and prolonged lysis times (LysT: 510 [4884, 5328]s) compared with those without MetS (MaxAbsC: 0.319 [0.310, 0.328]au, P=0.003; LysT: 7221 [6569, 7939]s, P<0.001). Furthermore, measures of clot structure/function increased progressively with increasing number of MetS components.

Conclusions—This study indicates that genetic factors contribute modestly to variance in clot structure/function and that clot structure/function is related to presence of the MetS and number of MetS components. Identification of the genetic and environmental factors influencing clot structure/function may further our understanding of the underlying factors predisposing to cardiovascular disease.


Key words: heritability • coagulation • fibrinolysis • metabolic syndrome • cardiovascular disease